Imatinib dose reduction after major molecular response in chronic‐phase chronic myeloid leukemia
Cancer · 2025
DOI: 10.1002/cncr.35565 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer, 2025. Verfasst von Zongru Li und 7 weiteren Autor:innen. Beteiligte Einrichtung: National Clinical Research Center for Hematologic Disease, Peking University Institute of Hematology, Peking University People's Hospital, Beijing, C…. Hauptthemen laut MEDLINE: Imatinib Mesylate, Leukemia, Myeloid, Chronic-Phase, Antineoplastic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Beijing Nova Program of Science and Technology, Peking University People's Hospital Research and Development Funds.
Abstract (Originalsprache)
Background
In people with chronic‐phase chronic myeloid leukemia (CML) receiving imatinib and achieving major molecular response (MMR), dose reduction may decrease adverse events but may be associated with a loss of molecular response. Whether digital droplet polymerase chain reaction (ddPCR) can identify persons in whom dose reduction might be unsuccessful is unknown.
Methods
Data from 716 consecutive subjects who achieved MMR after initial imatinib therapy (400 mg/day) were obtained. A total of 486 subjects remained on full‐dose imatinib, whereas 230 subjects had their dose reduced to 300 or 200 mg/day. The outcomes of these cohorts were compared via landmark and propensity score matching analyses.
Results
Imatinib dose reduction showed no significant effect on the subsequent achievement of deeper molecular responses (4‐ and 4.5‐log reductions in BCR::ABL1 transcripts; MR 4 and MR 4.5 ), maintenance of MMR, or attainment of therapy‐free remission when compared with subjects without dose reduction. In subjects achieving MR 4 , however, the probability of maintaining MR 4 ( p = .002) was lower in the reduced‐dose group. In multivariable analyses, failure to achieve MR 4.5 as determined by ddPCR at the time of dose reduction was significantly associated with briefer MMR failure‐free survival (FFS; hazard ratio [HR], 10.3; 95% confidence interval [CI], 1.3–82.9; p = .03) and MR 4 FFS (HR, 6.8; 95% CI, 2.6–18.0; p < .001).
Conclusions
Imatinib dose reduction after achieving MMR does not adversely affect response deepening or MMR maintenance in chronic‐phase CML but compromises MR 4 maintenance. The results of ddPCR may identify people who benefit from imatinib dose reduction.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Clinical Research Center for Hematologic Disease, Peking University Institute of Hematology, Peking University People's Hospital, Beijing, China.
- School of Biomedical Engineering, Tsinghua University, Beijing, China.
- TargetingOne Corporation, Beijing, China.
- Department of Immunology and Inflammation, Centre for Haematology, Imperial College London, London, UK.
- Peking University People's Hospital, Qingdao, China.
ORCID-Profile: Qian Jiang
Förderung
- National Natural Science Foundation of China
- Beijing Nova Program of Science and Technology
- Peking University People's Hospital Research and Development Funds
- Peking University Medicine Fund of Fostering Young Scholars' Scientific & Technological Innovation
Zitieren
APA
Li, Z., Zhang, X., Zhao, Y., Lu, L., Guo, Y., Gale, R. P., Qin, Y., & Jiang, Q. (2025). Imatinib dose reduction after major molecular response in chronic‐phase chronic myeloid leukemia. Cancer. https://doi.org/10.1002/cncr.35565
Vancouver
Li Z, Zhang X, Zhao Y, Lu L, Guo Y, Gale RP, et al. Imatinib dose reduction after major molecular response in chronic‐phase chronic myeloid leukemia. Cancer. 2025. doi:10.1002/cncr.35565
BibTeX
@article{Li2025,
author = {Li, Zongru and Zhang, Xiaoshuai and Zhao, Yijing and Lu, Linping and Guo, Yong and Gale, Robert Peter and Qin, Yazhen and Jiang, Qian},
title = {Imatinib dose reduction after major molecular response in chronic‐phase chronic myeloid leukemia},
journal = {Cancer},
year = {2025},
doi = {10.1002/cncr.35565}
}
EUVIMED